SCHEMBL3544608

SCHEMBL3544608

C=CCOc1ccc(C(=O)O)cc1OC(F)(F)F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.51
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
TSHR P16473 3/20 0.48
GAA P10253 2/20 0.48
MRGPRX4 Q96LA9 2/20 0.41
MAPT P10636 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA6 P23280 1/20 0.41
CA7 P43166 1/20 0.41
TPMT P51580 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41
PDE4B Q07343 1/20 0.40
FFAR1 O14842 1/20 0.40
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27051567 0.94 RXRA (0.49) KDM4ERXRARXRBRXRGTSHR
SCHEMBL15312851 0.87 KDM4E (0.60) KDM4ETSHRGAAMRGPRX4MAPT
SCHEMBL3367612 0.82 RXRA (0.54) KDM4ERXRARXRBRXRGTSHR
SCHEMBL1489132 0.82 RXRA (0.53) KDM4ERXRARXRBRXRGTSHR
SCHEMBL27051626 0.82 RXRA (0.42) KDM4ERXRARXRBRXRGTSHR
SCHEMBL31737057 0.81 KDM4E (0.74) KDM4ETSHRGAAMRGPRX4MAPT
SCHEMBL14907128 0.81 KDM4E (0.74) KDM4ETSHRGAAMRGPRX4MAPT
SCHEMBL2980229 0.80 TSHR (0.52) KDM4ETSHRGAAMRGPRX4MAPT
SCHEMBL27051568 0.80 RXRA (0.47) KDM4ERXRARXRBRXRGTSHR
SCHEMBL3314219 0.78 KDM4E (0.66) KDM4ETSHRGAAMRGPRX4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE KDM4E 2323/4885RXRA 4524/4885RXRB 4684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.